Researchers at ULg identify a new role of osteopontin in DNA repair and its impact on human glioblastoma radiosensitivity

Researchers at ULg identify a new role of osteopontin in DNA repair and its impact on human glioblastoma radiosensitivity

A team of scientists directed by Prof. A. Bellahcène and Prof. V. Castronovo, researchers at ULg’s GIGA research centre, has reported for the first time the impact of osteopontin (OPN) silencing on the radiosensitivity of glioblastoma (GBM) cells through interference with DNA double-strand repair machinery (Data published in Oncotarget).

GBM represents the most aggressive and common solid human brain tumor. ULg researchers have recently demonstrated the importance of osteopontin in the acquisition/maintenance of stemness characters and tumorigenicity of glioma initiating cells.

Based on the poor survival observed in OPN-high GBM patients, ULg’s researchers explored the consequence of OPN depletion on the survival of GBM cells after irradiation. They demonstrated that the inhibition of OPN in GBM cells impaired the activation of early signal transducers of DNA double-strand damage following ionizing radiation thus resulting in an enhanced radiosensitivity of GBM cells.

This discovery identifies OPN inhibition as a therapeutic target to counteract GBM radioresistance.

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials